
|Articles|February 26, 2014
- NSCLC (Issue 2)
- Volume 2
- Issue 1
Crizotinib Resistance in ALK-Positive Lung Cancer
Author(s)Alice T. Shaw, MD, PhD
Alice T. Shaw, MD, PhD, an attending physician in the Center for Thoracic Cancers at Massachusetts General Hospital, discusses resistance to crizotinib in patients with ALK-positive lung cancer
Advertisement
Alice T. Shaw, MD, PhD, an attending physician in the Center for Thoracic Cancers at Massachusetts General Hospital, discusses resistance to crizotinib in patients with ALK-positive lung cancer.
Learn more about thetreatment of ALK-positive lung cancer > >
Articles in this issue
over 12 years ago
Clinical Update: ALK-Positive NSCLCover 12 years ago
PD-L1 as a Biomarker for Immunotherapy Agents in Lung Cancerover 12 years ago
Treating Older Patients With NSCLCover 12 years ago
Treatment of Elderly Patients With NSCLCover 12 years ago
Current Challenges in Molecular Testing in NSCLCover 12 years ago
Individualized Maintenance Therapy for NSCLCover 12 years ago
Frontline Treatment Considerations in Non-Small Cell Lung CancerAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
2
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
3
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5

































